2019
Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial
Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, Tetrault JM, Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology 2019, 45: 319-326. PMID: 31590179, PMCID: PMC6901445, DOI: 10.1038/s41386-019-0536-z.Peer-Reviewed Original ResearchConceptsAlcohol drinking behaviorFirst treatment periodTreatment periodNumber of drinksCrossover trialDrinking behaviorEfficacy of naltrexoneOpioid antagonist naltrexoneNMDA antagonist memantinePositive family historyDay treatment periodSelf-administration periodAlcohol-induced stimulationAd lib accessMemantine treatmentAntagonist naltrexoneOpioid systemFamily historyNTXPriming drinkMemantineNaltrexoneAlcohol cravingHeavy drinkersAlcohol dependenceAssociation of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder
Yoon G, Petrakis IL, Krystal JH. Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder. JAMA Psychiatry 2019, 76: 337-338. PMID: 30624551, PMCID: PMC6439824, DOI: 10.1001/jamapsychiatry.2018.3990.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingAlcoholismCravingDepressive Disorder, MajorDrug Therapy, CombinationFemaleHumansKetamineMaleMiddle AgedNaltrexonePilot Projects
2017
Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service–Related Posttraumatic Stress Disorder
Byrne SP, Krystal JH, Rosenheck RA, Vessicchio J, Pietrzak RH. Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service–Related Posttraumatic Stress Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 717-721. PMID: 28945664, DOI: 10.1097/jcp.0000000000000777.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive AgentsAntipsychotic AgentsDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRandomized Controlled Trials as TopicRisperidoneSeverity of Illness IndexStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsVeteransConceptsPosttraumatic stress disorderAdjunctive risperidoneTreatment-resistant posttraumatic stress disorderClinician-Administered PTSD Scale scoresSymptom clustersStress disorderOriginal treatment regimenFirst-line pharmacotherapySpecific symptom clustersSpecific PTSD symptom clustersVeterans RANDTreatment regimenPharmacotherapeutic effectsHealth SurveyRole functioningPTSD symptom clustersTreat conditionScale scoreGreater severityVariable improvementRisperidoneTargeted pharmacotherapyPlaceboNonimprovementPharmacotherapyReevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach
Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA Psychiatry 2017, 74: 370-378. PMID: 28241180, PMCID: PMC5863470, DOI: 10.1001/jamapsychiatry.2017.0025.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAgedAntidepressive AgentsBupropionCitalopramCluster AnalysisDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDuloxetine HydrochlorideFemaleHumansMaleMianserinMiddle AgedMirtazapineRandomized Controlled Trials as TopicSleepSyndromeTreatment OutcomeVenlafaxine HydrochlorideYoung AdultConceptsCore emotional symptomsDepressive severitySymptom clustersHamilton Depression Rating ScaleDepression Outcomes trialDifferent antidepressant medicationsHAM-D scaleHigh-dose duloxetinePhase 3 trialEmotional symptomsPatient-reported dataDepression Rating ScaleSequenced Treatment AlternativesGroup of symptomsCluster of symptomsDepressive symptom checklistMixed-effects regression analysisDepressive Symptomatology ScaleAntidepressant therapyAntidepressant treatmentAntidepressant medicationOutcome trialsCombining MedicationsAtypical symptomsAdditional placebo
2011
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence
Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S, Treatment G. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. The World Journal Of Biological Psychiatry 2011, 12: 160-187. PMID: 21486104, DOI: 10.3109/15622975.2011.561872.Peer-Reviewed Original ResearchMeSH KeywordsAdultAryl Hydrocarbon HydroxylasesBuprenorphineCytochrome P-450 CYP2B6Cytochrome P-450 CYP2D6Drug Therapy, CombinationEvidence-Based MedicineGenetic VariationHumansMethadoneNarcotic AntagonistsNarcoticsOpiate Substitution TreatmentOpioid-Related DisordersOxidoreductases, N-DemethylatingPsychotherapyReceptors, OpioidSocial SupportStandard of CareSubstance Withdrawal SyndromeConceptsOpioid dependenceOpioid abusePractice guidelinesEvidence-based practice guidelinesBiological Psychiatry (WFSBP) GuidelinesOpioid agonist methadoneSecond-line medicationsNational treatment guidelinesNumber of medicationsEfficacy of methadoneOpioid use disorderEvidence-based guidelinesRandomized clinical trialsCombination of buprenorphineWorld FederationInternational task forceStrength of evidenceOpioid withdrawalAdjunctive medicationsOpioid maintenanceTreatment guidelinesTask ForceCochrane LibraryPharmacological treatmentClinical trials
2010
Baseline Trajectories of Drinking Moderate Acamprosate and Naltrexone Effects in the COMBINE Study
Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O’Malley S. Baseline Trajectories of Drinking Moderate Acamprosate and Naltrexone Effects in the COMBINE Study. Alcohol Clinical And Experimental Research 2010, 35: 523-531. PMID: 21143249, PMCID: PMC3062945, DOI: 10.1111/j.1530-0277.2010.01369.x.Peer-Reviewed Original Research
2009
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study
Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O’Malley S. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug And Alcohol Dependence 2009, 107: 221-229. PMID: 19969427, PMCID: PMC2821955, DOI: 10.1016/j.drugalcdep.2009.10.017.Peer-Reviewed Original Research
2007
Lamotrigine as Add-On Therapy in Schizophrenia
Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL. Lamotrigine as Add-On Therapy in Schizophrenia. Journal Of Clinical Psychopharmacology 2007, 27: 582-589. PMID: 18004124, DOI: 10.1097/jcp.0b013e31815abf34.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticonvulsantsAntipsychotic AgentsClozapineDiagnostic and Statistical Manual of Mental DisordersDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug ResistanceDrug Therapy, CombinationFemaleHumansLamotrigineMaleMiddle AgedPatient CompliancePatient DropoutsPsychiatric Status Rating ScalesSchizophreniaSeverity of Illness IndexSuicide, AttemptedTreatment OutcomeTriazinesConceptsNegative Syndrome Scale total scoreScale total scoreAntipsychotic medicationTotal scoreTreatment groupsSchizophrenia patientsPlacebo-controlled trialPrimary end pointParallel-group trialUse of lamotrigineClinical Global ImpressionAtypical antipsychotic medicationsResidual psychotic symptomsSymptom total scoreNegative Symptoms total scoreLamotrigine augmentationLamotrigine trialsRefractory psychosisAtypical antipsychoticsCognitive composite scoreWeek 12Global ImpressionTreat samplePsychotic symptomsLamotrigineThe resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings
Epperson CN, Amin Z, Naftolin F, Cappiello A, Czarkowski KA, Stiklus S, Anderson GM, Krystal JH. The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings. Journal Of Psychopharmacology 2007, 21: 414-420. PMID: 16891341, DOI: 10.1177/0269881106067330.Peer-Reviewed Original ResearchConceptsMenopausal womenTryptophan depletionSelective serotonin reuptake inhibitor fluoxetineAcute tryptophan depletion paradigmSerotonin reuptake inhibitor fluoxetineTryptophan depletion paradigmPathogenesis of depressionReuptake inhibitor fluoxetineMajor depressive episodeAcute tryptophan depletionRelapse of depressionWorsening of moodWeeks of recoveryActive tryptophan depletionWechsler Memory ScaleAssessment of moodDepressive episodeRisk factorsDepressive relapseMajor depressionSignificant worseningNeuroendocrine functionVerbal memorySerotonergic contributionMemory Scale
2006
Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms
Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms. Biological Psychiatry 2006, 61: 822-825. PMID: 17141740, PMCID: PMC2754299, DOI: 10.1016/j.biopsych.2006.08.037.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleHamilton Anxiety Rating ScaleTreatment-resistant depressionMajor depressive disorderHARS scoresRating ScaleExcessive glutamatergic neurotransmissionEffects of riluzoleDepression Rating ScaleResidual depressive symptomsAnxiety Rating ScaleRiluzole efficacyMedication regimenAugmentation therapyContinuation phaseAntidepressant activityGlutamate neurotransmissionGlutamatergic neurotransmissionDepressive disorderAnxiolytic effectsDepressive symptomsRiluzolePatientsFirst weekLinear mixed modelsVisual Hallucinations from the Addition of Riluzole to Memantine and Bupropion
Pittenger C, Naungayan C, Kendell S, Coric V, Malison R, Krystal JH, Sanacora GS. Visual Hallucinations from the Addition of Riluzole to Memantine and Bupropion. Journal Of Clinical Psychopharmacology 2006, 26: 218-220. PMID: 16633160, DOI: 10.1097/01.jcp.0000203228.64117.9f.Peer-Reviewed Original Research
2005
Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.
Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. The Journal Of Clinical Psychiatry 2005, 66: 1492-3. PMID: 16420092, DOI: 10.4088/jcp.v66n1121d.Peer-Reviewed Original Research
2004
Riluzole Augmentation for Treatment-Resistant Depression
Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole Augmentation for Treatment-Resistant Depression. American Journal Of Psychiatry 2004, 161: 2132-2132. PMID: 15514421, DOI: 10.1176/appi.ajp.161.11.2132.Peer-Reviewed Original Research
2001
Lamotrigine in the treatment of depersonalization disorder.
Sierra M, Phillips M, Lambert M, Senior C, David A, Krystal J. Lamotrigine in the treatment of depersonalization disorder. The Journal Of Clinical Psychiatry 2001, 62: 826-7. PMID: 11816874, DOI: 10.4088/jcp.v62n1012b.Peer-Reviewed Original ResearchAdultChronic DiseaseDepersonalizationDrug Therapy, CombinationFemaleHumansLamotrigineMaleTreatment OutcomeTriazines
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexone
1994
Precipitation of a Psychoneuromotor Syndrome by Fluoxetine in a Haloperidol-
D'SOUZA D, BENNETT A, ABI-DARGHAM A, KRYSTAL J. Precipitation of a Psychoneuromotor Syndrome by Fluoxetine in a Haloperidol-. Journal Of Clinical Psychopharmacology 1994, 14: 361-362. PMID: 7806697, DOI: 10.1097/00004714-199410000-00018.Peer-Reviewed Original ResearchShort-Term Use of Disulfiram With Clozapine
Brenner L, Karper L, Krystal J. Short-Term Use of Disulfiram With Clozapine. Journal Of Clinical Psychopharmacology 1994, 14: 213-214. PMID: 8027424, DOI: 10.1097/00004714-199406000-00016.Peer-Reviewed Original Research
1992
Valproate Management of Psychosis in a Patient with Carbamazepine-Induced Hyponatremia
KARPER L, SEIBYL J, KRYSTAL J. Valproate Management of Psychosis in a Patient with Carbamazepine-Induced Hyponatremia. Journal Of Clinical Psychopharmacology 1992, 12: 137-138. PMID: 1573038, DOI: 10.1097/00004714-199204000-00015.Peer-Reviewed Original ResearchControlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder
WOODS S, NAGY L, KOLESZAR A, KRYSTAL J, HENINGER G, CHARNEY D. Controlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder. Journal Of Clinical Psychopharmacology 1992, 12: 32-38. PMID: 1552038, DOI: 10.1097/00004714-199202000-00006.Peer-Reviewed Original Research
1990
Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder
McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. American Journal Of Psychiatry 1990, 147: 652-654. PMID: 1970224, DOI: 10.1176/ajp.147.5.652.Peer-Reviewed Original Research